<DOC>
	<DOCNO>NCT02820883</DOCNO>
	<brief_summary>This open-label , dose-escalation pilot study total 30 participant 10 per dosage group . The aim pilot study explore preliminary safety experimental recombinant staphylococcus aureus vaccine .</brief_summary>
	<brief_title>A Study Recombinant Staphylococcus Aureus Vaccine ( Escherichia Coli ) Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer age 18 65 year ( age 18 66 year ) . Able comply clinical trial protocol requirement willing complete visit plan process whole clinical trial observation period . Able understand content inform consent willing sign inform consent . Able complete diary card independently . For female ( 1849 year ) , negative urine pregnancy test willing practice continuous effective contraception study . Axillary temperature ≤37.0°C . First Immunization exclusion standard : Prior receipt Staphylococcus aureus vaccine Any confirm Staphylococcus aureus infection disease past 12 month . History asthma , hereditary angioneurotic edema , diabetes , malignancy serious disease . Participation clinical trial likely increase disease risk interfere observation clinical trial index . Prior blood donation Blood loss 400ml last 3 month ; Coagulation disorder ( coagulation factor deficiency , coagulopathy platelet disorder ) diagnose doctor , obvious bruise blood coagulation notice . History allergic disease likely exacerbate component vaccine , include allergy , urticaria , respiratory difficulty , angioneurotic edema abdominal pain . Any autoimmune disease immunodeficient state , parent , brother sister autoimmune disease immunodeficient disease . Taking immunoglobulin and/or blood product within last 12 month . Asplenia , functional asplenia asplenia cause situation splenectomy . Any acute disease acute attack chronic disease last 7 day . History thyroidectomy thyroid disease require treatment last 12 month . Immunosuppressor , cytotoxic therapy , inhale corticosteroid ( exclude corticosteroid spray treatment allergic rhinitis , acute nonconcurrent corticosteroid treatment ) Participation another research study involve receipt investigational product last 30 day . Woman breastfeed . Prior administration attenuate vaccine last 28 day . Prior administration subunit vaccine , inactivated vaccine allergic therapy last 14 day . Current antituberculosis prophylaxis therapy Any condition may compromise safety availability participant judgment investigator . Following Immunization exclusion standard : Any grade 3 serious adverse reaction happen since last vaccination . Other condition violate inclusion criterion meet exclusion criterion notice first immunization . Acute chronic infection vaccination day ( axillary temperature＞37.0°C ) . According investigator , participant continue participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>